Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Receivables (2019 - 2025)

Historic Receivables for X4 Pharmaceuticals (XFOR) over the last 5 years, with Q3 2025 value amounting to $1.6 million.

  • X4 Pharmaceuticals' Receivables rose 4967.38% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 4967.38%. This contributed to the annual value of $1.7 million for FY2024, which is 20427.05% up from last year.
  • As of Q3 2025, X4 Pharmaceuticals' Receivables stood at $1.6 million, which was up 4967.38% from $1.9 million recorded in Q2 2025.
  • Over the past 5 years, X4 Pharmaceuticals' Receivables peaked at $1.9 million during Q2 2025, and registered a low of $562000.0 during Q4 2023.
  • In the last 3 years, X4 Pharmaceuticals' Receivables had a median value of $1.2 million in 2025 and averaged $1.3 million.
  • Its Receivables has fluctuated over the past 5 years, first soared by 20427.05% in 2024, then skyrocketed by 4967.38% in 2025.
  • Over the past 3 years, X4 Pharmaceuticals' Receivables (Quarter) stood at $562000.0 in 2023, then soared by 204.27% to $1.7 million in 2024, then dropped by 6.08% to $1.6 million in 2025.
  • Its Receivables stands at $1.6 million for Q3 2025, versus $1.9 million for Q2 2025 and $1.2 million for Q1 2025.